Complete financial analysis of Movano Inc. (MOVE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Movano Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Pet Center Comércio e Participações S.A. (PETZ3.SA) Income Statement Analysis – Financial Results
- Biocon Limited (BIOCON.NS) Income Statement Analysis – Financial Results
- Wuxi NCE Power Co., Ltd. (605111.SS) Income Statement Analysis – Financial Results
- Nexen Tire Corporation (002355.KS) Income Statement Analysis – Financial Results
- Valeo SE (FR.PA) Income Statement Analysis – Financial Results
Movano Inc. (MOVE)
About Movano Inc.
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medtech and consumer devices. Its platform uses radiofrequency technology, which enables the creation of sensors that are small enough to fit into wearable devices and other small form factors. The company develops Movano Ring that measures heart rate, heart rate variability, sleep, respiration, temperature, blood oxygen saturation, steps, and calories, as well as incorporates women-centric features and design. It is also developing non-invasive continuous glucose monitoring and cuffless blood pressure monitoring features to its technology platform. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 158.00K | 134.00K | 74.00K | 13.00K | 11.00K | 3.00K |
| Gross Profit | -158.00K | -134.00K | -74.00K | -13.00K | -11.00K | -3.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.89M | 18.99M | 13.43M | 8.37M | 6.52M | 2.89M |
| General & Administrative | 0.00 | 1.93K | 6.38M | 2.73M | 2.00M | 662.18K |
| Selling & Marketing | 0.00 | 11.47M | 0.00 | 0.00 | 0.00 | -58.18K |
| SG&A | 12.80M | 11.47M | 6.38M | 2.73M | 2.00M | 604.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 72.00K | 0.00 |
| Operating Expenses | 29.69M | 30.46M | 19.80M | 11.11M | 8.51M | 3.49M |
| Cost & Expenses | 29.69M | 30.46M | 19.80M | 11.11M | 8.51M | 3.50M |
| Interest Income | 0.00 | 133.00K | 22.00K | 27.00K | 59.00 | 0.00 |
| Interest Expense | 0.00 | 133.00K | 883.00K | 1.00M | 0.00 | 0.00 |
| Depreciation & Amortization | 158.00K | 134.00K | 74.00K | 13.00K | 11.00K | 3.00K |
| EBITDA | -29.13M | -30.20M | -20.82M | -11.07M | -8.50M | -3.49M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.69M | -30.46M | -19.80M | -11.11M | -8.51M | -3.50M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 407.00K | 133.00K | -1.97M | -1.92M | 72.00K | 8.00K |
| Income Before Tax | -29.28M | -30.33M | -21.77M | -13.03M | -8.44M | -3.49M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -133.00K | 809.00K | 1.00M | -160.86K | 0.00 |
| Net Income | -29.28M | -30.20M | -22.58M | -14.04M | -8.44M | -3.49M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.51 | -13.71 | -10.34 | -6.55 | -3.94 | -1.63 |
| EPS Diluted | -9.51 | -13.71 | -10.34 | -6.55 | -3.94 | -1.63 |
| Weighted Avg Shares Out | 3.08M | 2.20M | 2.18M | 2.14M | 2.14M | 2.14M |
| Weighted Avg Shares Out (Dil) | 3.08M | 2.20M | 2.18M | 2.14M | 2.14M | 2.14M |
Movano Health Plans Response Submission to FDA Next Week as Part of EvieMED Final Review Phase
A successful response to requests for additional information would bring the Company one step closer to introducing this pioneering healthcare product to the market PLEASANTON, Calif. , Oct. 24, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it plans...
Movano Health Provides Update on FDA Review of EvieMED Ring
The Company continues to work closely with the FDA to bring this pioneering healthcare product to market PLEASANTON, Calif. , Oct. 10, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that the Company recently received additional clarifying questions from the...
Evie, Movano Health's Smart Ring for Women, is Back In Stock with Key Upgrades
Orders Reopen with Enhancements to AI Powered Health Insights, Sleep and Heart Rate Measurements and More PLEASANTON, Calif. , Sept. 17, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced the immediate availability of its Evie Ring , the first smart...
Movano Health Advances to Final Phase of FDA Review Process for EvieMED Ring
Following the positive outcome of a recent agency meeting, the Company will continue to work closely with the FDA to bring this pioneering healthcare product to market PLEASANTON, Calif. , Sept. 3, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today...
Movano Inc. (MOVE) Q2 2024 Earnings Call Transcript
Movano Inc. (NASDAQ:MOVE ) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants Jay Cogan - CFO John Mastrototaro - CEO Tyla Bucher - Chief Marketing Officer Michael Leabman - Founder and Chief Technology Officer Michael...
Movano Health Reports Q2 2024 Financial Results and Provides Business Update
Prepares for September 17, 2024, Evie Ring back in stock date Announces brand partnership with digital creator Heidi D'Amelio Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif....
Movano Health to Report Second Quarter 2024 Financial Results on Wednesday August 14, 2024
Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif. , Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report second quarter 2024 financial and operating results on...
Movano Health Provides Progress Update on EvieMED Regulatory Filing
Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif. , Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE ) plans to meet with the FDA in mid-August, as part of the Company's...
Movano Health Announces Dr. Fatima Rodriguez Joining July 11 Virtual Event
Allele Capitals' Matt Hughes will moderate future forward panel on enterprise need in wearables for a variety of healthcare applications PLEASANTON, Calif. , June 28, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced the addition of two expert participants to its...
Movano Health Applies Advanced AI through Deep Learning to Deliver Improved Accuracy of Heart Rate in Motion
Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications PLEASANTON, Calif., June 13, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE ) announced major advances in the accuracy of its heart rate in motion algorithm following...
Source: https://incomestatements.info
Category: Stock Reports